When further adjusted for anti-diabetes drug usage in glucose metabolism traits or lipid-lowering drug usage in the lipid profile (model 3), RBP4 was significantly associated with fasting and 2-h post-loading glucose [β=0.26 (0.05, 0.47), P=0.02, and β=1.70 (1.29, 2.12), P< 0.0001], serum triglycerides [β=0.75, 95% CI (0.54, 0.96), P<0.0001], and total cholesterol [β=0.47, 95% CI (0.23 0.70), P<0.0001]. The gene discussed is RBP4; the disease is diabetes mellitus.